Skip to main content
SpringerLink
Log in

Hepatisch metastasiertes kolorektales Karzinom

Evidenz und perspektive interventionell radiologischer Techniken

  • Chapter
Weiterbildung Onkologie

  • 1551 Accesses

Zusammenfassung

Neben der systemischen (Kombinations-)Chemotherapie und Tumorchirurgie können Metastasen des kolorektalen Karzinoms effektiv durch bildgestützte, lokale thermische Verfahren, wie z. B. der Radiofrequenz- oder Mikrowellenablation (RFA bzw. MWA) oder der interstitiellen Hochdosisraten (HDR)-Brachytherapie sowie lokoregionären Therapieansätzen wie der selektiven internen Radiotherapie (SIRT) oder transarteriellen Chemoemboli- sation mit „drug-eluting beads“ (DEB-TACE) behandelt werden. Die genannten Methoden ermöglichen eine lokale Tumorkontrolle bei geringer Invasivität und weitgehender Vermeidung systemischer Nebenwirkungen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 9.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 17.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ferlay J, Parkin DM, Stellarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765–781

    Article  CAS  PubMed  Google Scholar 

  2. Manfredi S, Lepage C, Flatem C et al (2006) Epidemiology and management of liver métastasés from colorectal cancer. Ann Surg 244:254–259

    Article  PubMed  PubMed Central  Google Scholar 

  3. Van Cutsem E, Kohne CH, Lang I et al (2011) Cetuximab plus Irinotecan, fiuorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019

    Article  PubMed  Google Scholar 

  4. Van Cutsem E, Nordlinger B, Cervantes A (2010) Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 21 (Suppl 5):v93–v97

    Article  PubMed  Google Scholar 

  5. Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Khatri VP, Chee KG, Petrelli NJ (2007) Modem multimodality approach to hepatic colorectal métastasés: solutions and controversies. Surg Oncol 16:71–83

    Article  PubMed  Google Scholar 

  7. Welsh FK, Tekkis PP, O’RourkeT et al (2008) Quantification of risk of a positive (R1) resection margin following hepatic resection for metastatic colorectal cancer: an aid to clinical decision-making. Surg Oncol 17:313

    Article  Google Scholar 

  8. Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver métastasés following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 1138–47

    Google Scholar 

  9. Folprecht G, Gruenberger T, Bechstein W et al (2014) Survival of patients with initially unresectable colorectal liver métastasés treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 25:10181025

    Article  Google Scholar 

  10. Garufi C, Torsello A, Tumolo S et al (2010) Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver métastasés: POCHER trial. Br J Cancer 103:1542–1547

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254–1261

    Article  CAS  PubMed  Google Scholar 

  12. Bokemeyer C, Van Custem E, Rougier P et al (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48:14661475

    Article  Google Scholar 

  13. Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. VanTilborg AA, Meijerink MR, Sietses C et al (2011) Long-term results of radiofrequency ablation for unresectable colorectal liver métastasés: a potentially curative intervention. Br J Radiol 84:556–565

    Article  CAS  Google Scholar 

  15. Schmoll HJ, Van Custem E, Stein A et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer, a personalized approach to clinical decision making. Ann Oncol 23:24792516

    Article  Google Scholar 

  16. Glllams AR, Lees WR (2009) Five-year survival in 309 patients with colorectal liver métastasés treated with radiofrequency ablation. Eur Radiol 19:1206–1213

    Article  Google Scholar 

  17. Mulier S, Mulier P, Ni Y et al (2002) Complications of radiofrequency coagulation of liver tumours. Br J Surg 89:1206–1222

    Article  CAS  PubMed  Google Scholar 

  18. Shlbata T, Niinobu T, Ogata N et al (2000) Microwave coagulation therapy for multiple hepatic métastasés from colorectal carcinoma. Cancer 89:276–284

    Article  Google Scholar 

  19. Wang J, Liang P, Yu J et al (2014) Clinical outcome of ultrasound-guided percutaneous microwave ablation on colorectal liver métastasés. Oncol Lett 8:323–326

    PubMed  PubMed Central  Google Scholar 

  20. Liang P, Wang Y, Yu X et al (2009) Malignant liver tumors: treatment with percutaneous microwave ablation - complications among cohort of 1136 patients. Radiology 251333–940

    Google Scholar 

  21. Ricke J, Mohnike K, Pech M et al (2010) Local response and impact on survival after local ablation of liver métastasés from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 78:479485

    Article  Google Scholar 

  22. Hendlisz A, Van den Eynde M, Peeters M et al (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28:3687–3694

    Article  CAS  PubMed  Google Scholar 

  23. Seidensticker R, Denecke T, Kraus P et al (2012) Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 35:1066–1073

    Article  PubMed  Google Scholar 

  24. Cosimelli M, Golfieri R, Cagol PP et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103:324–331

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Martin RC, Joshi J, Robbins K et al (2011) Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 18:192–198

    Article  PubMed  Google Scholar 

  26. Fiorentini G, Aliberti C, Tilli M et al (2012) Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32:1387–1395

    CAS  PubMed  Google Scholar 

  27. Rossi S, Fornari F, Pathies C et al (1990) Thermal lesions induced by 480 KHz localized current field in guinea pig and pig liver. Tumori 76:5457

    Google Scholar 

  28. Pereira PL, Clasen S, Boss A et al (2004) Radiofrequency ablation of IF ver metastases. Radiologe 44:347357

    Article  Google Scholar 

  29. Pereira PL, Dux M, Helmberger T et al (2012) Perkutane bildgesteuerte Leber-Tumortherapie mittels Radiofrequenz-Ablation (RFA). Deutsche Gesellschaft fur Interventlonelle Radiologie und minimal-invasive Therapie. http://v2.degir.de/download/dokman/Leitlinie-RFA:

  30. Mulier S, Ni Y, Jamart J et al (2005) Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 242:158171

    Article  Google Scholar 

  31. Erce C, Parks RW (2003) Interstitial ablative techniques for hepatic tumours. Br J Surg 90:272–289

    Article  CAS  PubMed  Google Scholar 

  32. RuersT, Punt C, Van Coevorden F et al (2012) Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver métastasés: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 23:26192626

    Google Scholar 

  33. Boutros C, Somasundar P, Garrean S et al (2010) Microwave coagulation therapy for hepatic tumors: review of the literature and critical analysis. Surg Oncol 19:e22–e32

    Article  CAS  PubMed  Google Scholar 

  34. Wright AS, Sampson LA, Warner TF et al (2005) Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 236:132–139

    Article  PubMed  Google Scholar 

  35. Pathak S, Jones R, Tang JM et al (2011) Ablative therapies for colorectal liver métastasés: a systematic review. Colorectal Dis 13:e252–e265

    Article  CAS  PubMed  Google Scholar 

  36. Bala MM, Riemsma RP, Wolff R et al (2013) Microwave coagulation for liver métastasés. Cochrane Database Syst Rev 10:CD010163. doi:10.1002/14651858.CD010163. pub2 (CD010163)

    PubMed  Google Scholar 

  37. Ricke J, Wust P, Wieners G et al (2004) Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vase Interv Radiol 15:12791286

    Google Scholar 

  38. Ricke J, Thormann M, Ludewig M et al (2010) MR-guided liver tumor ablation employing open high-field 1.0 T MRI for image-guided brachytherapy. Eur Radiol 20:1985–1993

    Article  PubMed  Google Scholar 

  39. Wieners G, Pech M, Hildebrandt B et al (2009) Phase II feasibility study on the combination of two different regional treatment approaches in patients with colorectal „liver-only“ métastasés: hepatic Interstitial brachytherapy plus regional chemotherapy. Cardiovasc Intervent Radiol 32:937945

    Article  Google Scholar 

  40. Streitparth F, Pech M, Bohmig M et al (2006) In vivo assessment of the gastric mucosal tolerance dose after single fraction, small volume Irradiation of liver malignancies by computed tomography-guided, high-dose- rate brachytherapy. Int J Radiat Oncol Biol Phys 65:1479–1486

    Article  PubMed  Google Scholar 

  41. Wybranski C, Seidensticker M, Mohnike K et al (2009) In vivo assessment of dose volume and dose gradient effects on the tolerance dose of small liver volumes after singlefraction high-dose-rate 192lr irradiation. Radiat Res 172:598–606

    Article  CAS  PubMed  Google Scholar 

  42. Ricke J, Seidensticker M, Ludemann L et al (2005) In vivo assessment of the tolerance dose of small liver volumes after single-fraction HDR Irradiation. Int J Radiat Oncol Biol Phys 62:776–784

    Article  PubMed  Google Scholar 

  43. Ruhl R, Ludemann L, Czarnecka A et al (2010) Radiobiological restrictions and tolerance doses of repeated single-fraction HDR-irradiatlon of Intersecting small liver volumes for recurrent hepatic métastasés. Radiat Oncol 5:44

    Article  PubMed  PubMed Central  Google Scholar 

  44. Salem R, Thurston KG (2006) Radioembolization with 90Yttrlum microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1:Technical and méthodologie considerations. J Vase Interv Radiol 17:1251–1278

    Article  Google Scholar 

  45. Salem R, Thurston KG (2006) Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vase Interv Radiol 17:1571–1593

    Article  Google Scholar 

  46. Salem R, Thurston KG (2006) Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vase Interv Radiol 17:1425–1439

    Article  Google Scholar 

  47. Kennedy AS, Nutting C, Coldwell D et al (2004) Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60:1552–1563

    Article  CAS  PubMed  Google Scholar 

  48. Wang LM, Jani AR, Hill EJ et al (2013) Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver métastasés. J Clin Pathol 66:205–211

    Article  CAS  PubMed  Google Scholar 

  49. Kennedy A, Nag S, Salem R et al (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68:13–23

    Article  PubMed  Google Scholar 

  50. Denecke T, Ruhl R, Hlldebrandt B et al (2008) Planning transarterial radloembolizatlon of colorectal liver métastasés with Yttrium 90 microspheres: evaluation of a sequential diagnostic approach using radiologic and nuclear medicine imaging techniques. Eur Radiol 18:892–902

    Article  PubMed  Google Scholar 

  51. Seidensticker R, Seidensticker M, Damm R et al (2012) Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach. Cardiovasc Intervent Radiol 35:1109–1118

    Article  PubMed  Google Scholar 

  52. Zarva A, Mohnike K, Damm R et al (2014) Safety of repeated radioembolizations in patients with advanced primary and secondary liver tumors and progressive disease after first selective internal radiotherapy. J Nucl Med 55:360–366

    Article  PubMed  Google Scholar 

  53. Goin JE, Salem R, Carr Bl et al (2005) Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vase Interv Radiol 16:195–203

    Article  Google Scholar 

  54. Hazel GA van, Pavlakis N, Goldstein D et al (2009) Treatment of fluorouracil-refractory patients with liver métastasés from colorectal cancer by using yttrium-90 resin mlcrosphe res plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 27:4089–4095

    Article  PubMed  Google Scholar 

  55. Evans KA, Richardson MG, Pavlakis N et al (2010) Survival outcomes of a salvage patient population after radioembolization of hepatic métastasés with yttrium-90 microspheres. J Vase Interv Radiol 21:1521–1526

    Article  Google Scholar 

  56. Mulcahy MF, Lewandowskl RJ, Ibrahim SM et al (2009) Radioembolization of colorectal hepatic métastasés using yttrium-90 microspheres. Cancer 115:1849–1858

    Article  PubMed  Google Scholar 

  57. Fiorentlni G, Aliberti C, Mulazzani L et al (2014) Chemoembollzation in colorectal liver métastasés: the rebirth. Anticancer Res 34:575–584

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Radiologie und Nuklearmedizin, Universitätsklinik Magdeburg, Magdeburg

    C. Wybranski, A. Gazis & J. Ricke

Authors
  1. C. Wybranski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Gazis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Ricke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Marienhospital Herne – Klinik für Strahlentherapie, Ruhr-Universität Bochum, Herne, Deutschland

    Irenäus A. Adamietz

  2. Zentrum der Chirurgie – Universität Frankfurt, Universitätsklinikum Frankfurt, Frankfurt, Deutschland

    Wolf O. Bechstein

  3. Strahlentherapie Spez Onkol, Medizinische Hochschule Hannover, Göttingen, Deutschland

    Hans Christiansen

  4. Urologikum Lübeck, Lübeck, Deutschland

    Christian Doehn

  5. Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Deutschland

    Andreas Hochhaus

  6. Interdisziplin. Tumorzentrum, Universität Mannheim, TagesTherapieZentrum TTZ, Mannheim, Deutschland

    Ralf-Dieter Hofheinz

  7. Klinik für Gynäkologie, Charité – Universitätsmedizin Berlin, Berlin, Deutschland

    Werner Lichtenegger

  8. Cancer Center, Universitätsklinikum Leipzig, Leipzig, Deutschland

    Florian Lordick

  9. Klinik für Dermatologie, Universitätsklinikum Essen, Essen, Deutschland

    Dirk Schadendorf

  10. Klinik Gynäkologie/Geburtshilfe, HELIOS Klinikum Berlin-Buch, Berlin, Deutschland

    Michael Untch

  11. Institut für Pathologie, Universitätsklinikum Leipzig, Leipzig, Deutschland

    Christian Wittekind

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Wybranski, C., Gazis, A., Ricke, J. (2016). Hepatisch metastasiertes kolorektales Karzinom. In: Adamietz, I., et al. Weiterbildung Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49415-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-49415-8_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-49414-1

  • Online ISBN: 978-3-662-49415-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation